An evolutionary approach to cancer chemotherapy scheduling

Genetic Programming and Evolvable Machines

Volumn 8, Issue 4, 2007, Pages 301-318

  Ochoa, Gabriela ^a   Villasana, Minaya ^b   Burke, Edmund K ^a  

^a UNIVERSITY OF NOTTINGHAM   (United Kingdom)

^b UNIVERSIDAD SIMÓN BOLÍVAR   (Venezuela)

Author keywords

Cancer chemotherapy; Cancer model; Cycle phase specific drugs; Evolution strategies; Evolutionary algorithms; Objective function; Optimal control

Indexed keywords

CANCER CHEMOTHERAPY; CANCER MODELS; EVOLUTION STRATEGIES; OBJECTIVE FUNCTION;

CELL CULTURE; DECISION SUPPORT SYSTEMS; EVOLUTIONARY ALGORITHMS; OPTIMAL CONTROL SYSTEMS; PATIENT TREATMENT; TUMORS;

CHEMOTHERAPY;

EID: 36148967279     PISSN: 13892576     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10710-007-9041-y     Document Type: Article

References (18)

1. Chuang, L., Lotzova, E., Cook, K., Cristoforoni, P., Morris, M., Wharton, T.: Effect of new investigational drug taxol on oncolytic activity and stimulation of human lymphocytes. Gynecol. Oncol. 49, 291-298 (1993)
2. de Pillis, L., Radunskaya, A.: The dynamics of an optimally controlled tumor model: a case study. Math. Comput. Model. 37(11), 1221-1244 (2003)
3. de Pillis, L., Radunskaya, A.: A mathematical tumor model with immune resistance and drug therapy: an optimal control approach. J. Theor. Med. 3, 79-100 (2001)
4. Hansen, N., Ostermeier, A.: Completely derandomized self-adaptation in evolution strategies. Evol. Comput. 9(2), 159-195 (2001)
5. Hansen, N., Ostermeier, A.: (1996) Adapting arbitrary normal mutation distributions in evolution strategies: the covariance matrix adaptation. In: Proceedings of the 1996 IEEE International Conference on Evolutionary Computation, pp. 312-317. IEEE Press, Piscataway, NJ
6. Hardman, J., Linbird, L.: Goodman and Gilman's the pharmacological basis of therapeutics, 9th edn. McGraw-Hill, New York (1996)
7. Luus, R.: Iterative dynamic programming, monographs and surveys in pure and applied mathematics, vol. 110. Chapman and Hall, New York (2000)
8. Morrison, R.W., De Jong K.A.: Measurement of population diversity. In: Hartmanis, J., Goos, G., van Leeuwnen, J. (eds) Proceedings of Artificial Evolution: 5th International Conference, Evolution Artificielle (EA 2001), LNCS, vol. 2310, pp. 31-41. Springer, Berlin (2002)
9. Panetta, J.C., Adam, J.: A mathematical model of cycle-specific chemotherapy. Math. Compt. Model. 22(2), 67-82 (1995)
10. Petrovski, A., McCall, J.: Multi-objective optimisation of cancer chemotherapy using evolutionary algorithms. In: Zitzler, E., Deb, K., Thiele, L., Coello Coello C. A., Corne D. (eds.) Proceedings of Evolutionary Multi-Criterion Optimization, First International Conference, EMO 2001, LNCS, vol. 1993, pp. 531-545. Springer, Berlin (2001)
11. Petrovski. A., Shakya, S., McCall, J.: Optimising cancer chemotherapy using an estimation of distribution algorithm and genetic algorithms. In: Cattolico, M. (ed.) Genetic and Evolutionary Computation Conference, GECCO 2006, vol. 1, pp. 413-418. ACM Press, Washington (2006)
12. Petrovski, A., Sudha, B., McCall, J.: Optimising cancer chemotherapy using particle swarm optimisation and genetic algorithms. In: Yao, X., Burke, E. K., Lozano, J.A., Smith, J., Merelo Guervós, J. J., Bullinaria, J. A., Rowe, J. E., Tiño, P., Kabán, A., Schwefel, H.-P. (eds.) Parallel Problem Solving from Nature-PPSN VIII, LNCS, vol. 3242, pp. 633-641. Springer, Berlin (2004)
13. Sear, J.: Clinics in anaesthesiology, vol. 2. Intravenous anaesthesiology, no. 1, ch. 12, p. 223. W. B. Saunders, Philadelphia (1984)
14. Villasana, M.: A delay differential equation model for tumor-immune system interactions, Ph.D. thesis, Claremont Graduate University (2001)
15. Villasana, M., Ochoa, G.: Heuristic design of cancer chemotherapy, IEEE trans. Evol. Comput. 8(6), 513-521 (2004)
16. Villasana, M., Radunskaya, A.: A delay differential equation model for tumor growth. J. Math. Biol. 47, 270-294 (2003)
17. Wheldon, T.: Mathematical models in cancer research. Adam Hilger, Bristol, Philadelphia (1998)
18. Zoli, W., Flamigni, A., Frassineti, G., Bajorko, P., De Paola, F., Milandri, C., Amadori, D., Gasperi-Campani, A.: In vitro activitity of taxol and toxotere in comparison with doxorubicin and cisplatin on primary cell cultures of human breast cancers. Breast Cancer Res. Treat. 34, 63-69 (1995)